Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Potential breakthrough in osteoarthritis treatment

Rat experiments could see new pain relieving injections

Pain relieving injections for osteoarthritis sufferers (OA) which avoid the risk of hyperthermia and potentially eliminate the need for surgery, have been discovered in experiments using rats.

At the moment people experiencing the severe pain associated with OA are offered pain relieving drugs such as steroid injections and anti-inflammatory drugs, which reduce inflammation.
Severe side effects, however, limit their use.

Previous clinical trials to block pain receptor TRPV1 failed as they had adverse effects on body temperature, resulting in hyperthermia.

Now researchers from The University of Nottingham have experimented with 176 rats to see whether this side effect can be avoided by an injection directly to the joint.

Dr Sara Kelly, a lecturer in neuroscience at the university, and one of the lead researchers on the project, said: “Using a model of human osteoarthritis pain we wanted to investigate if by blocking these receptors locally within the diseased joint, could we reduce the pain caused by osteoarthritis, without the side effect of hyperthermia — and the answer is yes.
 
“Osteoarthritis is a very common disease and the pain it causes is severe and can last a life time.

"A lot of patients who suffer with osteoarthritis are elderly and it would be better if we could treat their pain by giving them a drug, rather than putting them through a major surgical procedure like a joint replacement.

"The annual cost of joint replacement to the NHS is close to £200 million, which is another reason to look for a more effective solution.
 
“By targeting the joint directly, we did not see the side effect of hyperthermia, which is thought to be generated outside of the joint at the level of abdominal organs."

Clinical trials in human patients will now need to be undertaken.

In this country alone, osteoarthritis affects more than eight million people. An ageing population and growing obesity epidemic will see this figure rise.
 
Prof Alan Silman, medical director of Arthritis Research UK, which funded the research, said: “We desperately need new approaches to treating the pain of osteoarthritis.

"For some years this particular pathway has shown potential as a means by which osteoarthritic pain may be transmitted, but until now attempts at blocking this pathway have caused unacceptable side-effects.
 
“This research seems to suggest it might be possible to overcome this and to provide a novel and effective approach to targeting osteoarthritis.”

To view the full research paper — Increased Function of Pronociceptive TRPV1 at the Level of the Joint in a Rat Model of Osteoarthritis Pain — click here. 
 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.